Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization

0539375 - BTÚ 2021 RIV CH eng J - Článek v odborném periodiku
Nováková, Zora - Bělousová, Nikola - Foss, C. A. - Havlínová, Barbora - Grešová, Markéta - Das, Gargi - Lisok, A. - Přáda, A. - Barinkova, M. - Hubálek, Martin - Pomper, M. - Bařinka, Cyril
Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.
International Journal of Molecular Sciences. Roč. 21, č. 18 (2020), č. článku 6672. E-ISSN 1422-0067
Grant CEP: GA MŠMT(CZ) LTAUSA18196; GA MŠMT(CZ) LM2015043; GA ČR(CZ) GA18-04790S; GA MŠMT(CZ) LM2015062; GA MŠMT(CZ) EF16_013/0001775; GA MŠMT(CZ) ED1.1.00/02.0109
Institucionální podpora: RVO:86652036 ; RVO:61388963
Klíčová slova: single-chain fv * human prostate-cancer * membrane antigen psma * monoclonal-antibody
Obor OECD: Biochemistry and molecular biology; Analytical chemistry (UOCHB-X)
Impakt faktor: 5.924, rok: 2020
Způsob publikování: Open access
https://www.mdpi.com/1422-0067/21/18/6672

Prostate-Specific Membrane Antigen (PSMA) is an established biomarker for the imaging and experimental therapy of prostate cancer (PCa), as it is strongly upregulated in high-grade primary, androgen-independent, and metastatic lesions. Here, we report on the development and functional characterization of recombinant single-chain Fv (scFv) and Fab fragments derived from the 5D3 PSMA-specific monoclonal antibody (mAb). These fragments were engineered, heterologously expressed in insect S2 cells, and purified to homogeneity with yields up to 20 mg/L. In vitro assays including ELISA, immunofluorescence and flow cytometry, revealed that the fragments retain the nanomolar affinity and single target specificity of the parent 5D3 antibody. Importantly, using a murine xenograft model of PCa, we verified the suitability of fluorescently labeled fragments for in vivo imaging of PSMA-positive tumors and compared their pharmacokinetics and tissue distribution to the parent mAb. Collectively, our data provide an experimental basis for the further development of 5D3 recombinant fragments for future clinical use.
Trvalý link: http://hdl.handle.net/11104/0317066